The market for sepsis and septic shock across the seven major pharmaceutical markets of the US, France, Germany, Italy, Spain, the UK, and Japan is expected to reach $5.9bn by 2026, according to a report by GlobalData.

Titled ‘Opportunity Analyzer: Sepsis and Septic Shock – Opportunity Analysis and Forecasts to 2026’ the report forecasts the sepsis and septic shock market to witness a compound annual growth rate (CAGR) of 7.9%, growing from $2.8bn in 2016.

Annual sales of sepsis drugs across the 7MM were approximately $2.2bn in 2016, while those of septic shock drugs were $600m.

Sepsis, a complex disease that causes organ dysfunction(s), has a high level of unmet need due to the absence of licensed products specific to the disease treatment across the 7MM.

"The US market will witness the launch of two medical devices in the future, namely Toraymyxin and CytoSorb."

Four new first-in-class pipeline drugs, namely BMS-936559, recAP, Traumakine, and CYT107, while three improved therapeutics, namely selepressin, thrombomodulin and cefiderocol are expected to be launched in the market in future, which will in turn drive the market growth.

The US market will witness the launch of two medical devices in the future, namely Toraymyxin and CytoSorb.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sepsis treatments currently in pipeline target disseminated intravascular coagulopathy, acute lung injury, and acute kidney injury, but future opportunities will be in the development of novel therapies targeting comorbid conditions, says Christopher Pace, Director of the Infectious Disease team at GlobalData.

Involvement of multiple organs in sepsis and septic shock, however, poses a major hindrance to the development of safe, effective and tolerable treatment agents, the report adds.